KR102638678B1 - 헤테로시클릭 화합물 - Google Patents

헤테로시클릭 화합물 Download PDF

Info

Publication number
KR102638678B1
KR102638678B1 KR1020197031604A KR20197031604A KR102638678B1 KR 102638678 B1 KR102638678 B1 KR 102638678B1 KR 1020197031604 A KR1020197031604 A KR 1020197031604A KR 20197031604 A KR20197031604 A KR 20197031604A KR 102638678 B1 KR102638678 B1 KR 102638678B1
Authority
KR
South Korea
Prior art keywords
group
alkyl
substituted
membered
substituents selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197031604A
Other languages
English (en)
Korean (ko)
Other versions
KR20200027917A (ko
Inventor
노부유키 마쯔나가
다카시 나카하타
유타 다나카
히로키 다카하기
야스후미 미야모토
레이 오카모토
다케시 요시카와
요시토 데라오
다카후미 유카와
게이코 가케가와
요이치 니시카와
데루후미 다카기
마사시 다카하시
말라레디 코맨들라
릴리 쿽
릴리 ?o
조안 미우라
마크 사바트
니콜라스 스코라
폴 타니스
존 티호나스
퐁 에이치. 부
하이시아 왕
시아오룬 왕
준야 시라이
도모히로 오카와
젠유 시오카와
아키토 시부야
Original Assignee
카듀리온 파마슈티칼스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 카듀리온 파마슈티칼스, 인크. filed Critical 카듀리온 파마슈티칼스, 인크.
Publication of KR20200027917A publication Critical patent/KR20200027917A/ko
Application granted granted Critical
Publication of KR102638678B1 publication Critical patent/KR102638678B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
KR1020197031604A 2017-03-27 2018-03-23 헤테로시클릭 화합물 Active KR102638678B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762476970P 2017-03-27 2017-03-27
US62/476,970 2017-03-27
PCT/US2018/024043 WO2018183112A1 (en) 2017-03-27 2018-03-23 Heterocyclic compound

Publications (2)

Publication Number Publication Date
KR20200027917A KR20200027917A (ko) 2020-03-13
KR102638678B1 true KR102638678B1 (ko) 2024-02-19

Family

ID=63671942

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197031604A Active KR102638678B1 (ko) 2017-03-27 2018-03-23 헤테로시클릭 화합물

Country Status (9)

Country Link
US (2) US10543212B2 (https=)
EP (1) EP3600327A4 (https=)
JP (1) JP7249950B2 (https=)
KR (1) KR102638678B1 (https=)
CN (1) CN110799190B (https=)
AU (1) AU2018243691B2 (https=)
CA (1) CA3058182A1 (https=)
TW (1) TWI789381B (https=)
WO (1) WO2018183112A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7249950B2 (ja) 2017-03-27 2023-03-31 カーデュリオン・ファーマシューティカルズ・リミテッド・ライアビリティ・カンパニー ヘテロ環化合物
EP3728228A1 (en) 2017-12-22 2020-10-28 Ravenna Pharmaceuticals, Inc. Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
WO2020068846A1 (en) * 2018-09-25 2020-04-02 Heterocyclic Compound Heterocyclic compound
IL281765B2 (en) 2018-09-25 2024-04-01 Cardurion Pharmaceuticals Inc Aminopyrimidine compound
EP3902805A4 (en) 2018-12-28 2023-03-01 SPV Therapeutics Inc. CYCLINE-DEPENDENT KINASE INHIBITORS
TW202112767A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
CA3157525A1 (en) * 2019-10-25 2021-04-29 Gilead Sciences, Inc. Glp-1r modulating compounds
WO2021154796A1 (en) 2020-01-29 2021-08-05 Gilead Sciences, Inc. Glp-1r modulating compounds
MY207021A (en) * 2020-03-18 2025-01-24 Lg Chemical Ltd Glp-1 receptor agonist, pharmaceutical composition comprising same, and method for preparing same
CN115279750B (zh) * 2020-03-18 2024-06-21 株式会社Lg化学 Glp-1受体激动剂、包含该激动剂的药物组合物及其制备方法
TW202229273A (zh) 2020-09-28 2022-08-01 美商卡都瑞恩醫藥有限責任公司 稠合雜芳基化合物及其作為CaMKII抑制劑之用途
EP4247804A1 (en) 2020-11-20 2023-09-27 Gilead Sciences, Inc. Polyheterocyclic glp-1 r modulating compounds
EP4304711A1 (en) 2021-03-11 2024-01-17 Gilead Sciences, Inc. Glp-1r modulating compounds
WO2022192430A1 (en) 2021-03-11 2022-09-15 Gilead Sciences, Inc. Glp-1r modulating compounds
WO2022216094A1 (ko) * 2021-04-08 2022-10-13 주식회사 엘지화학 Glp-1 수용체 효능제, 이를 포함하는 약학적 조성물 및 이의 제조방법
PH12023552860A1 (en) 2021-04-21 2024-05-20 Gilead Sciences Inc Carboxy-benzimidazole glp-1r modulating compounds
CA3242372A1 (en) 2021-12-29 2023-07-06 Psy Therapeutics, Inc. Inhibiting monoacylglycerol lipase (magl)
WO2023130050A1 (en) * 2021-12-29 2023-07-06 Psy Therapeutics, Inc. Monoacylglycerol lipase inhibitors and use thereof for the treatment and management of pain
CN114621312B (zh) * 2022-03-24 2022-11-15 陕西师范大学 一种寡肽烷基侧链的选择性修饰方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004510707A (ja) 2000-08-08 2004-04-08 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 神経保護性の２−ピリジナミン組成物および関係する方法
WO2010057833A1 (en) 2008-11-21 2010-05-27 Biomarin Iga, Ltd. Compounds for treatment of duchenne muscular dystrophy
JP2010523568A (ja) * 2007-04-05 2010-07-15 アムジエン・インコーポレーテツド オーロラキナーゼ調節物質及び使用方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2423050A1 (en) 2000-09-20 2002-03-28 Ortho-Mcneil Pharmaceutical, Inc. Pyrazine derivatives as modulators of tyrosine kinases
EP1648875A1 (en) * 2003-07-30 2006-04-26 Cyclacel Limited 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
JP2007504229A (ja) 2003-09-02 2007-03-01 メルク　エンド　カムパニー　インコーポレーテッド 代謝調節型グルタミン酸受容体−５のモジュレーターとしてのビピリジルアミン類およびエーテル類
WO2009032703A1 (en) 2007-08-28 2009-03-12 Irm Llc 2- (het) arylamino-6-aminopyridine derivatives and fused forms thereof as anaplastic lymphoma kinase inhibitors
TW201016676A (en) * 2008-10-03 2010-05-01 Astrazeneca Ab Heterocyclic derivatives and methods of use thereof
AU2011328237A1 (en) 2010-11-09 2013-05-23 Cellzome Limited Pyridine compounds and aza analogues thereof as TYK2 inhibitors
EP2763976B1 (en) 2011-10-05 2016-05-18 Merck Sharp & Dohme Corp. 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors
PT2840080T (pt) 2012-04-17 2018-02-06 Fujifilm Corp Composto heterocíclico que contém azoto ou sal do mesmo
JP7249950B2 (ja) * 2017-03-27 2023-03-31 カーデュリオン・ファーマシューティカルズ・リミテッド・ライアビリティ・カンパニー ヘテロ環化合物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004510707A (ja) 2000-08-08 2004-04-08 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 神経保護性の２−ピリジナミン組成物および関係する方法
JP2010523568A (ja) * 2007-04-05 2010-07-15 アムジエン・インコーポレーテツド オーロラキナーゼ調節物質及び使用方法
WO2010057833A1 (en) 2008-11-21 2010-05-27 Biomarin Iga, Ltd. Compounds for treatment of duchenne muscular dystrophy

Also Published As

Publication number Publication date
US20180280389A1 (en) 2018-10-04
JP7249950B2 (ja) 2023-03-31
TW201904959A (zh) 2019-02-01
EP3600327A1 (en) 2020-02-05
CN110799190B (zh) 2024-04-19
CN110799190A (zh) 2020-02-14
JP2020515575A (ja) 2020-05-28
US11197858B2 (en) 2021-12-14
WO2018183112A1 (en) 2018-10-04
EP3600327A4 (en) 2020-10-28
CA3058182A1 (en) 2018-10-04
AU2018243691A1 (en) 2019-10-24
US10543212B2 (en) 2020-01-28
KR20200027917A (ko) 2020-03-13
AU2018243691B2 (en) 2022-05-12
TWI789381B (zh) 2023-01-11
US20200230137A1 (en) 2020-07-23

Similar Documents

Publication Publication Date Title
KR102638678B1 (ko) 헤테로시클릭 화합물
AU2016284654B2 (en) 2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic M1 receptor
CA3071825A1 (en) Heterocyclic compound
US12528816B2 (en) Substituted imidazo [1,2-b] pyridazines and [1, 2, 4] triazolo [ 4,3-b] pyridazines as camkii inhibitors
US20230117295A1 (en) Nitrogen containing heterocycles as cdk12 inhibitors
JP2026010092A (ja) 複素環化合物
KR102946104B1 (ko) 아미노피리미딘 화합물
EA052559B1 (ru) Конденсированные гетероарильные соединения и их применение в качестве ингибиторов camkii

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20191025

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210316

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230517

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20231121

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240215

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240215

End annual number: 3

Start annual number: 1

PG1601 Publication of registration